HEALTH

ATLANTA According to new data compiled by the Centers for Disease Control and Prevention that covers use of smokeless tobacco in all 50 states, the District of Columbia, the U.S. Virgin Islands, Puerto Rico and Guam released Thursday, the rates of smokers who also use smokeless tobacco, including chew tobacco and snuff, range from 0.9% in Puerto Rico to 13.7% in Wyoming.

EAST BRUNSWICK, N.J. Drug maker Savient Pharmaceuticals will begin shipping its treatment for chronic gout to specialty distributors at the end of this month, Savient said.

The company announced that it would begin shipping Krystexxa (pegloticase) on Nov. 30, and it would become available for prescription on Dec. 1.

ALEXANDRIA, Va. Lansinoh Labs on Thursday went live with its new online portal, called "Lansinoh Professional" (LansinohProfessional.com), that will provide International board-certified lactation consultants, registered nurses, midwives, doulas, OB/GYNs and other healthcare providers with the resources they need to better educate and support breast-feeding moms.

NEW YORK KidKupz on Tuesday announced its new medicine-dispensing cups soon will be available nationwide through Walgreens.

The KidKupz are fruit-flavored medicine dispensing cups that contain 2 g of sugar and no high-fructose corn syrup.

CONCORD, Mass. Two scientific papers published in Nutrition Reviews and the American Journal of Clinical Nutrition addressed a link between heart health and a diet that includes grapes or grape-based products.

DEERFIELD, Ill. The healthcare landscape is changing. There’s a new value-driven consumer who has emerged and, in light of this, retail pharmacy giant Walgreens is in the midst of an evolution into “a retail health and daily living store” and is on a mission to “own well.” That was a key message that an optimistic Greg Wasson, Walgreens president and CEO, had for Wall Street during the company’s Analyst Day conference on Thursday in Chicago.

WASHINGTON Nearly 100 drugs are in development for treating Alzheimer’s disease, according to a new report by the main lobby for the pharmaceutical industry.

The Pharmaceutical Research and Manufacturers of America said 98 medicines for dementia, mostly Alzheimer’s, were in clinical trials or under review by the Food and Drug Administration.